natgillin/translations-raw huggingface dataset:
Daklinza is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus. 
Zdravilo Daklinza je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. nalezljivo boleznijo jeter, ki jo povzroča virus
The company that markets Daklinza will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Daklinza. 
Družba, ki trži zdravilo Daklinza, bo za oceno tveganja ponovitve raka jeter po zdravljenju z neposredno delujočimi protivirusnimi zdravili, kot je zdravilo Daklinza, izvedla študijo pri bolnikih, ki so preboleli raka jeter.
Regarding its safety, Daklinza was well tolerated and the side effects were similar to those experienced 
Kar zadeva varnost, so bolniki zdravilo Daklinza dobro prenašali, neželeni učinki pa so bili podobni kot pri bolnikih, ki so prejemali placebo.
For the full list of all side effects reported with Daklinza, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Daklinza, glejte navodilo za
For practical information about using Daklinza, patients should read the package leaflet or contact their 
Za praktične informacije o uporabi zdravila Daklinza naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Almost all the patients in the main study had the virus cleared from their blood. 
Pri skoraj vseh bolnikih, ki so sodelovali v glavni študiji, je
Daklinza used in combination with sofosbuvir (with or without ribavirin) was effective at clearing the hepatitis C virus from the blood in a main study involving 211 adults. 
V glavni študiji, v katero je bilo vključenih 211 odraslih bolnikov, je bilo zdravilo Daklinza, uporabljeno v kombinaciji s sofosbuvirjem (z ribavirinom ali brez njega), učinkovito pri odstranjevanju virusa hepatitisa C iz krvi.
Further information can be found in the summary of the risk management plan. 
Dodatne informacije so na voljo v povzetku načrta za obvladovanje tveganja.
Other side effects seen were uncommon, mild and short-lived. 
Ostali neželeni učinki so bili občasni, blagi in kratkotrajni.
The European Commission granted a marketing authorisation valid throughout the European Union for Lymphoseek on 19 November 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Lymphoseek, veljavno po vsej Evropski uniji, izdala 19. novembra 2014.
What measures are being taken to ensure the safe and effective use of Lymphoseek? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lymphoseek?
The full EPAR and risk management plan summary for Lymphoseek can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta za obvladovanja tveganja za zdravilo Lymphoseek sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This helps to decide if further surgery to remove more lymph nodes is needed. 
To pomaga pri odločitvi, ali so potrebni nadaljnji posegi, da bi odstranili več bezgavk.
This is a summary of the European public assessment report (EPAR) for Lymphoseek. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lymphoseek.
Given the importance of locating lymph nodes in the treatment of cancers and the manageable side effects seen with Lymphoseek, the Committee concluded that its benefits are greater than its risks and recommended that it be approved for use in the EU. 
Glede na pomen lociranja bezgavk pri zdravljenju raka in na obvladljivost neželenih učinkov, opaženih pri zdravilu Lymphoseek, je odbor zaključil, da so njegove koristi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
It contains the active substance tilmanocept. 
Vsebuje zdravilno učinkovino tilmanocept.
The most common side effects with Lymphoseek seen in clinical studies are pain and irritation at the injection site (seen in less than 1 patient in 100). 
Najpogostejša neželena učinka zdravila Lymphoseek, opažena v kliničnih študijah, sta bila bolečina in draženje na mestu injiciranja (opažena pri manj kot 1 bolniku od 100).
Other information about Lymphoseek 
Druge informacije o zdravilu Lymphoseek
It is not intended to provide practical advice on how to use Lymphoseek. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
A risk management plan has been developed to ensure that Lymphoseek is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Lymphoseek je bil pripravljen načrt za obvladovanje tveganja.
A special camera that detects radiation is then used to see where the lymph nodes are and therefore where the cancer is likely to spread. 
S posebno kamero, ki zaznava sevanje, se nato ugotavlja, kje so bezgavke in s tem kam se bo rak najverjetneje razširil.
For more information about treatment with Lymphoseek, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Lymphoseek preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Lymphoseek? 
Kakšna tveganja so povezana z zdravilom Lymphoseek?
Before being injected into the patient, Lymphoseek is ‘radiolabelled', which means that it is tagged with a small amount of radiation. 
Preden se injicira bolniku, se zdravilo Lymphoseek „radiološko označi“, kar pomeni, da se mu doda majhna količina snovi, ki oddaja sevanje.
What benefits of Lymphoseek have been shown in studies? 
Kakšne koristi je zdravilo Lymphoseek izkazalo v študijah?
What is Lymphoseek and what is it used for? 
Kaj je zdravilo Lymphoseek in za kaj se uporablja?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Lymphoseek, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Lymphoseek in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In these two studies, doctors were able to detect a higher number of sentinel lymph nodes with Lymphoseek than with the blue dye: almost all of the lymph nodes identified using the blue dye (98% in one study and 100% in the other) were identified using Lymphoseek, while only around 70% and 60%, respectively, of the lymph nodes detected using Lymphoseek were detected with the blue dye. 
V teh dveh študijah so zdravniki z zdravilom Lymphoseek odkrili večje število varovalnih bezgavk kakor z modrim barvilom: skoraj vse bezgavke, ki jih je zaznalo modro barvilo, je zaznalo tudi zdravilo Lymphoseek (98 % v prvi študiji in 100 % v drugi), medtem ko je modro barvilo odkrilo le okoli 70 % oziroma 60 % bezgavk, ki jih je odkrilo zdravilo Lymphoseek.
The benefits of Lymphoseek were shown in two main studies in which 311 patients with breast or skin cancer had their lymph nodes first mapped with Lymphoseek and then with another method involving the use of a dye known as ‘vital blue dye'. 
Koristi zdravila Lymphoseek so bile dokazane v dveh glavnih študijah, v katerih so 311 bolnikom z rakom dojke ali kožnim rakom mapirali bezgavke, in sicer najprej z zdravilom Lymphoseek, nato pa z drugo metodo, ki vključuje uporabo „vitalnega modrega barvila“.
Why is Lymphoseek approved? 
Zakaj je bilo zdravilo Lymphoseek odobreno?
In a third study in patients with cancer of the head and neck including mouth cancer, Lymphoseek was used to detect sentinel lymph nodes before patients had their lymph nodes removed surgically. 
V tretji študiji pri bolnikih z rakom glave in vratu, vključno z rakom ust, so zdravilo Lymphoseek uporabili za zaznavanje varovalnih bezgavk, preden so bolnikom bezgavke kirurško odstranili.
Lymphoseek should only be used by healthcare professionals with expertise in mapping lymph nodes. 
Zdravilo Lymphoseek naj uporabljajo le zdravstveni delavci z izkušnjami pri mapiranju bezgavk.
For practical information about using Lymphoseek, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Lymphoseek naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Lymphoseek is used in patients with breast cancer, melanoma (a skin cancer) and a type of cancer of the mouth known as squamous cell carcinoma. 
Zdravilo Lymphoseek se uporablja pri bolnikih z rakom dojke, melanomom (kožnim rakom) in vrsto raka ust, imenovano skvamozni karcinom.
Because it attaches to these proteins, the radiolabelled medicine builds up in the lymph nodes surrounding the cancer, making them visible with the special camera. 
Z vezavo na omenjene beljakovine se to radiološko označeno zdravilo nakopiči v bezgavkah okoli raka, zaradi česar so vidne s posebno kamero.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that studies showed that the use of Lymphoseek led to a higher detection rate for sentinel lymph nodes than the use of vital blue dye. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je ugotovil, da so študije pokazale, da je bilo z zdravilom Lymphoseek zaznano večje število varovalnih bezgavk kakor z vitalnim modrim barvilom.
The active substance in Lymphoseek, tilmanocept, attaches to proteins called mannose binding proteins which are found in high amounts in certain immune cells in the lymph nodes. 
Zdravilna učinkovina zdravila Lymphoseek, tilmanocept, se veže na beljakovine, ki vežejo manozo, te pa je mogoče v velikih količinah najti v določenih imunskih celicah v bezgavkah.
If the sentinel nodes are found to have no cancer then more extensive lymph nodal surgery can be avoided. 
Če v varovalnih bezgavkah ne odkrijejo raka, se je mogoče izogniti obsežnejšemu kirurškemu posegu na bezgavkah.
The blue dye is used during surgery to stain the lymph nodes so they can be seen and then checked for cancerous tissue. 
Modro barvilo se uporablja med kirurškim posegom, da obarva bezgavke, ki tako postanejo vidne in je mogoče preveriti, ali vsebujejo rakavo tkivo.
Almost all the patients (38 out of 39) with cancerous lymph nodes were identified by Lymphoseek. 
Zdravilo Lymphoseek je bilo v skoraj vseh primerih (38 od 39) uspešno pri odkrivanju rakavih bezgavk.
The sentinel lymph nodes are the regional lymph nodes where the cancer is likely to spread to first. 
Varovalne bezgavke so regionalne bezgavke, na katere se rak najverjetneje najprej razširi.
How is Lymphoseek used? 
Kako se zdravilo Lymphoseek uporablja?
For the full list of all side effects and restrictions with Lymphoseek, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Lymphoseek, glejte navodilo za uporabo.
Lymphoseek is a diagnostic medicine used in patients with cancer to identify sentinel lymph nodes. 
Zdravilo Lymphoseek se uporablja v diagnostične namene pri bolnikih z rakom za zaznavanje varovalnih bezgavk.
How does Lymphoseek work? 
Kako zdravilo Lymphoseek deluje?
Lymphoseek is a solution that is injected either around or inside the cancerous tissue and and is expected to attach to and build up in the nearby lymph nodes. 
Zdravilo Lymphoseek je raztopina, ki se injicira v bližino ali notranjost rakavega tkiva.
When sentinel lymph nodes are found they are removed surgically and checked for cancer cells. 
Ko odkrijejo varovalne bezgavke, jih kirurško odstranijo in nato preverijo, ali vsebujejo rakave celice.
The lymph nodes can then be checked for cancer cells. 
Nato je mogoče preveriti, ali bezgavke vsebujejo rakave celice.
The safety data and details from this program are presented in section 5.1. 
Podatki o varnosti in podrobnosti o tem programu so predstavljeni v poglavju 5.1.
It may also cause inflammation in other areas of the body. 
Povzroča lahko tudi vnetje v drugih delih telesa.
(See sections 4.3 and 4.4.) 
(Glejte poglavji 4.3 in 4.4.)
• You are elderly (i.e., over 65 years of age). 
• ste starejši (tj. nad 65 let).
These can increase your risk of heart disease. 
Ti dejavniki lahko povečajo tveganje za bolezni srca.
• if you are under 16 years of age 
• če ste mlajši od 16 let.
If you are elderly (i.e., over 65 years of age), your doctor will want to appropriately keep a check on you. 
Če ste starejši (tj. nad 65 let), vas bo vaš zdravnik temu primerno nadzoroval.
Your doctor will want to discuss your treatment from time to time. 
Zdravnik se bo občasno želel pogovoriti z vami o vašem zdravljenju.
The potential for human risk in pregnancy is unknown. 
Možno tveganje pri nosečnicah ni znano.
There was an increase in digoxin Cmax (approximately 33%). 
Prišlo je do povečanja Cmax digoksina (približno za 33 %).
Overall Safety: 
Varnost v celoti:
• if you are or could be pregnant or are breast-feeding (see ‘Pregnancy and breast feeding') 
• če ste ali bi lahko bili noseči ali če dojite (glejte 'Nosečnost in dojenje').
Therefore, France sent a notification that was received by the EMEA on 19 September 2007 and a referral under Article 6 (12) of Commission Regulation EC No 1084/2003 was started on 20 September 2007. 
Zato je Francija poslala uradno obvestilo, ki ga je Evropska agencija za zdravila prejela 19. septembra 2007, napotitveni postopek v skladu s členom 6(12) Uredbe Komisije (ES) št. 1084/2003 pa se je začel 20. septembra 2007.
- The Committee considered the referral made under Article 6(12) of Commission Regulation EC No 1084/2003, for Arcoxia and associated names. 
- Odbor je preučil napotitev v skladu s členom 6(12) Uredbe Komisije (ES) št. 1084/2003 za zdravilo Arcoxia in z njim povezana imena.
However, most hepatic adverse experiences in the MEDAL Program were non-serious. 
Večina jetrnih neželenih dogodkov v programu MEDAL ni bila resnih.
The absolute risk increase for such events is unlikely to exceed 1% per year based on existing data (uncommon). 
Glede na obstoječe podatke je malo verjetno, da absolutno povečanje tveganja za te dogodke preseže 1 % na leto (občasni).
Relative Risk (95% CI) 
relativno tveganje (95 % IZ)
These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). 
Ti spadajo v družino zdravil, ki jih imenujemo nesteroidna protivnetna zdravila (NSAR-i).
PRT Quinta da FonteEdifício Vasco da Gama, 19 - Porto Salvo Paço d' Arcos 
PRT Quinta da FonteEdifício Vasco da Gama, 19 - Porto Salvo
National competent authorities (NCA) shall ensure that the following conditions are fulfilled by the marketing authorisation holders: 
Nacionalni pristojni organ zagotovi, da imetniki dovoljenja za promet z zdravilom izpolnjujejo naslednje pogoje:
The rate of absorption was affected, resulting in a 36% decrease in Cmax and an increase in Tmax by 2 hours. 
Vplivalo je na hitrost absorpcije in povzročilo 36 % zmanjšanje Cmax in podaljšanje Tmax za 2 uri.
It is important that you use the lowest dose that controls your pain and you should not take <ARCOXIA> for longer than necessary. 
Pomembno je, da jemljete najmanjši odmerek, ki vam ublaži bolečino, in da zdravila <ARCOXIA> ne jemljete dalj časa, kot je potrebno.
What is gout? 
Kaj je protin?
Therefore: 
Zato:
This medicinal product is authorized in the Member States of the EEA under the following names: Austria 
To zdravilo ima dovoljenje za promet v državah članicah EGP pod naslednjimi imeni:
Do not take more than the recommended dose for your condition. 
Ne vzemite večjega odmerka od priporočenega za vašo bolezen.
Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled. 
Bolniki z visokim krvnim tlakom, ki je daljše obdobje povišan nad 140/90mmHg in ni zadostno nadzorovan.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS / MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJEV / IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
• You have a history of high blood pressure. 
• ste kdaj imeli visok krvni tlak.
Rare (occurring in greater than 1 out of 10,000 and less than 1 out of 1000 people) Low blood levels of sodium. 
Redki (pojavijo se pri več kot 1 od 10.000 in manj kot 1 od 1000 oseb) Zmanjšanje vrednosti natrija v krvi.
It results from the gradual breakdown of cartilage that cushions the ends of the bones. 
Je posledica postopne obrabe hrustanca, ki prekriva končne dele kosti.
The CHMP therefore recommends the strengthening of the contraindication in hypertensive patients and alerts prescribers that blood pressure needs to be monitored, especially within 2 weeks of treatment initiation. 
CHMP zato priporoča okrepitev kontraindikacije pri bolnikih s povišanim krvnim tlakom in zdravstvene delavce, ki zdravilo predpisujejo, opozarja, da je treba krvni tlak nadzorovati, zlasti v obdobju dveh tednov po uvedbi zdravljenja.
Approximately 50% of patients enrolled in the MEDAL study had a history of hypertension at baseline. 
Približno 50 % bolnikov, vključenih v študijo MEDAL, je ob vključitvi imelo anamnezo o hipertenziji.
Diclofenac (N=16483) 24766 PatientYears 
diklofenak (N = 16.483) 24.766 bolnik-let (patient-years)
• You have a history of heart failure, heart attack or any other form of heart disease. 
• ste kdaj imeli srčno popuščanje, srčni napad ali katerokoli drugo bolezen srca.
• You are dehydrated, for example by a prolonged bout of vomiting or diarrhoea. 
• ste dehidrirani, na primer zaradi dolgotrajnega bruhanja ali driske.
This is because the risk of heart attacks and strokes might increase after prolonged treatment, especially with high doses. 
To je zaradi tveganja za srčni napad in kap, ki se pri daljšem zdravljenju lahko poveča, še posebej pri velikih odmerkih.
If you miss a dose, just resume your usual schedule the following day. 
Če ste izpustili odmerek, nadaljujte z jemanjem zdravila naslednji dan ob običajnem času.
The CHMP therefore recommends that dose finding studies are explored to conclude if treatment with 60mg once daily would also be adequate for some patients. 
Zato CHMP priporoča, da se posebej preučijo študije o odmerjanju za ugotovitev, ali bi zdravljenje z odmerkom 60 mg enkrat dnevno zadostovalo za določene bolnike.
If you take more <ARCOXIA> than you should You should never take more tablets than the doctor recommends. 
Če ste vzeli večji odmerek zdravila <ARCOXIA>, kot bi smeli Nikoli ne vzemite več tablet, kot vam jih je predpisal zdravnik.
• if you have high blood pressure that has not been controlled by treatment (check with your doctor or nurse if you are not sure whether your blood pressure is adequately controlled) 
• če imate visok krvni tlak, ki kljub zdravljenju ni ustrezno nadzorovan (če niste prepičani, če je vaš tlak ustrezno nadzorovan, se posvetujte s svojim zdravnikom ali z medicinsko sestro).
Elderly: Pharmacokinetics in the elderly (65 years of age and older) are similar to those in the young. 
Starejši bolniki: Farmakokinetika pri starejših bolnikih (starih 65 let ali več) je podobna kot pri mlajših bolnikih.
This leaflet was last approved in (MM/YYYY). 
Navodilo je bilo odobreno: (MM/LLLL).
Paediatric patients: The pharmacokinetics of etoricoxib in paediatric patients (<12 years old) have not been studied. 
Pediatrični bolniki: Farmakokinetike etorikoksiba pri pediatričnih bolnikih (< 12 let) niso preučevali.
The cardiorenal results for EDGE and EDGE II were consistent with those described for the MEDAL Study. 
Kardiorenalni rezultati študij EDGE in EDGE II so v skladu z rezultati, opisanimi za študijo MEDAL.
Patients enrolled in the Program had a wide range of cardiovascular and gastrointestinal risk factors at baseline. 
Bolniki, vključeni v program, so v izhodišču imeli raznolike kardiovaskularne in gastrointestinalne dejavnike tveganja.
<ARCOXIA> Tablets are available in four strengths: 
Zdravilo <ARCOXIA> je na voljo v štirih jakostih:
These beneficial effects were maintained over the 12-week treatment periods. 
Ti koristni učinki so trajali celotno 12-tedensko obdobje zdravljenja.
Very rare: renal insufficiency, including renal failure, usually reversible upon discontinuation of treatment (see section 4.4). 
Zelo redke: ledvična insuficienca, vključno z odpovedjo ledvic, ki je običajno reverzibilna po ukinitvi zdravljenja (glejte poglavje 4.4)
These beneficial effects were observed as early as the second day of therapy and maintained for up to 52 weeks. 
Ti koristni učinki so se pojavili že drugi dan zdravljenja in se ohranili do 52 tednov.
• <ARCOXIA> is one of a group of medicines called selective COX-2 inhibitors. 
• Zdravilo <ARCOXIA> je eno izmed zdravil iz skupine zdravil, imenovanih selektivni zaviralci COX-2.
LIST OF EXCIPIENTS Lactose (see leaflet for more information). 
SEZNAM POMOŽNIH SNOVI Laktoza (za več informacij glejte Navodilo za uporabo).
Very rare: urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis. 
Zelo redke: urtikarija, Stevens-Johnson-ov sindrom, toksična epidermalna nekroliza
In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive therapy, if required. 
V primeru prevelikega odmerjanja so primerni običajni podporni ukrepi, npr. odstranitev neabsorbiranega zdravila iz prebavil ter uvedba kliničnega nadzora in podpornega zdravljenja, če je to potrebno.
Very rare: bronchospasm. 
Zelo redke: bronhospazem
- A direct healthcare professional communication (DHPC) must be sent to all healthcare professionals who prescribe etoricoxib according to national practice. 
− Dopis „Spoštovani zdravstveni delavec“ (DHPC) mora biti poslan vsem zdravstvenim delavcem, ki lahko v skladu z nacionalno prakso predpisujejo etorikoksib.
What is ankylosing spondylitis? 
Kaj je ankilozirajoči spondilitis?
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10). 
Huda motnja delovanja jeter (serumski albumin < 25 g/l ali ocena po Child-Pugh ≥ 10).
The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4). 
Odločitev, da se predpiše selektivni zaviralec COX-2, mora temeljiti na oceni vseh tveganj za vsakega posameznega bolnika (glejte poglavji 4.3 in 4.4).
Pregnancy and lactation (see sections 4.6 and 5.3). 
Nosečnost in dojenje (glejte poglavji 4.6 in 5.3).
Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. 
Diuretiki, zaviralci ACE in antagonisti angiotenzina II: NSAR-i lahko zmanjšajo učinek diuretikov in drugih antihipertenzivnih zdravil.
Take special care with <ARCOXIA> <ARCOXIA> may not be suitable for you, or you may need to be monitored regularly while taking it if any of the following apply to you: 
Bodite posebno pozorni pri uporabi zdravila <ARCOXIA> Zdravilo <ARCOXIA> morda ni primerno za vas ali pa morate biti, medtem ko ga jemljete, pod rednim nadzorom zdravnika, če za vas velja kaj od naštetega:
In studies specifically designed to measure the onset of action of etoricoxib, the onset of action occurred as early as 24 minutes after dosing. 
V študijah, ki so jih zasnovali posebej za določitev začetka delovanja etorikoksiba, je delovanje nastopilo že 24 minut po odmerjanju.
Overall upper GI events were defined as perforations, ulcers and bleeds. 
Dogodki v zgornjem predelu prebavil so v celoti definirani kot perforacije, ulkusi in krvavitve.
These interactions should be considered in patients taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists. 
Te interakcije je treba upoštevati pri bolnikih, ki jemljejo etorikoksib sočasno z zaviralci ACE ali antagonisti angiotenzina II.